Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

SAT0221 Survival in lupus patients with end-stage renal disease: A brazilian cohort

Identifieur interne : 001172 ( Main/Exploration ); précédent : 001171; suivant : 001173

SAT0221 Survival in lupus patients with end-stage renal disease: A brazilian cohort

Auteurs : F. M. Ribeiro [Brésil] ; C. L. Fabris ; I. Bendet [Brésil] ; J. R. Lugon

Source :

RBID : ISTEX:A7B7080A6053EA00FC190B7DC7F537E8803BAC2F

English descriptors

Abstract

Background Ten to twenty-five percent of systemic lupus erythemathosus (SLE) patients will progress to end-stage renal disease (ESRD). Data about the survival rate of lupus patients on dialysis is controversial. Objectives The present study reports the survival of SLE patients undergoing dialysis and analyzes factors associated with mortality. Methods Twenty dialysis centers were visited between May/2003 and February/2004. Disease activity was evaluated using the SLE disease activity index (SLEDAI) without the renal related parameters (nrSLEDAI); Clinical examination and laboratory tests were performed at entrance in the study. The control group consisted of hemodialysis patients without SLE, matched for gender, race, age, time on dialysis, and hepatitis C virus (HCV) infection. Patients were followed for 60 months. The end-point was death of any cause. Kaplan-Meier method was used to estimate survival. Associations of risk factors with mortality were tested with the Cox proportional hazards model. Results Each group was composed of 57 patients. The group of SLE tended to have a slightly shorter time on dialysis (54±50 months vs. 71±53 months, P=0.0829). Twelve patients (21%) in each group had HCV infection. The prevalence of flare in SLE patients approached 44%. The 1- and 5-year survival rates of SLE patients and controls were 88 and 70%, 93 and 84%, respectively. When analyzing the Kaplan Meier curves, survival of the control group and the one from SLE patients with nrSLEDAI ≤8 were similar but significantly better than the one of SLE patients with nrSLEDAI>8 (P<0.001). In the univariate analysis, only nrSLEDAI (either as a continuous or a categorical variable, HR 1.176, 95%CI 1.043-1.326, P=0.008, and HR 5.746, 95%CI 1.983-16.651, P=0.001, respectively), immunosuppressive use (HR 2.713, 95%CI 1.032-7.133, P=0.043), and URR (HR 0.967, 95% CI 0.930-1.005, P=0.086) were significantly associated with mortality. In the multivariate analysis, only nrSLEDAI>8 (HR 6.368, 95%CI 1.798-22.548, P=0.004), and URR (HR 0.953, 95%CI 0.917-0.990, P=0.014) emerged as independent factors associated with mortality in lupus patients. Conclusions A high nrSLEDAI was strongly associated with five year mortality in lupus patients on dialysis. Disclosure of Interest None Declared

Url:
DOI: 10.1136/annrheumdis-2012-eular.3168


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">SAT0221 Survival in lupus patients with end-stage renal disease: A brazilian cohort</title>
<author>
<name sortKey="Ribeiro, F M" sort="Ribeiro, F M" uniqKey="Ribeiro F" first="F. M." last="Ribeiro">F. M. Ribeiro</name>
</author>
<author>
<name sortKey="Fabris, C L" sort="Fabris, C L" uniqKey="Fabris C" first="C. L." last="Fabris">C. L. Fabris</name>
</author>
<author>
<name sortKey="Bendet, I" sort="Bendet, I" uniqKey="Bendet I" first="I." last="Bendet">I. Bendet</name>
</author>
<author>
<name sortKey="Lugon, J R" sort="Lugon, J R" uniqKey="Lugon J" first="J. R." last="Lugon">J. R. Lugon</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A7B7080A6053EA00FC190B7DC7F537E8803BAC2F</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2012-eular.3168</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-WH15LLSC-8/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001067</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001067</idno>
<idno type="wicri:Area/Istex/Curation">001067</idno>
<idno type="wicri:Area/Istex/Checkpoint">000224</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000224</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Ribeiro F:sat:survival:in</idno>
<idno type="wicri:Area/Main/Merge">001173</idno>
<idno type="wicri:Area/Main/Curation">001172</idno>
<idno type="wicri:Area/Main/Exploration">001172</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">SAT0221 Survival in lupus patients with end-stage renal disease: A brazilian cohort</title>
<author>
<name sortKey="Ribeiro, F M" sort="Ribeiro, F M" uniqKey="Ribeiro F" first="F. M." last="Ribeiro">F. M. Ribeiro</name>
<affiliation wicri:level="3">
<country>Brésil</country>
<placeName>
<settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
<wicri:orgArea>Rheumatology, Universidade Do Estado Do Rio De Janeiro</wicri:orgArea>
</affiliation>
<affiliation wicri:level="3">
<country>Brésil</country>
<placeName>
<settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
<wicri:orgArea>Rheumatology, Universidade Do Estado Do Rio De Janeiro</wicri:orgArea>
</affiliation>
</author>
<author>
<name sortKey="Fabris, C L" sort="Fabris, C L" uniqKey="Fabris C" first="C. L." last="Fabris">C. L. Fabris</name>
<affiliation></affiliation>
<affiliation>
<wicri:noCountry code="subField">Niteroi</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Bendet, I" sort="Bendet, I" uniqKey="Bendet I" first="I." last="Bendet">I. Bendet</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Immunology, Laboratόrio Sérgio Franco, Rio de Janeiro</wicri:regionArea>
<placeName>
<settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Immunology, Laboratόrio Sérgio Franco, Rio de Janeiro</wicri:regionArea>
<placeName>
<settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lugon, J R" sort="Lugon, J R" uniqKey="Lugon J" first="J. R." last="Lugon">J. R. Lugon</name>
<affiliation></affiliation>
<affiliation>
<wicri:noCountry code="subField">Niteroi</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">71</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="546">546</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Anticardiolipin antibodies</term>
<term>Antiphospholipid antibody</term>
<term>Clinical phenotypes</term>
<term>Cognitive dysfunction</term>
<term>Cohort</term>
<term>Control group</term>
<term>Current prednisone dose</term>
<term>Dental implants</term>
<term>Diabetes mellitus</term>
<term>Diagnosis years</term>
<term>Diagnostic utility</term>
<term>Disease activity</term>
<term>Disease activity index</term>
<term>Focal sialadenitis</term>
<term>High disease activity</term>
<term>Higher disease activity</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive therapy</term>
<term>Implant</term>
<term>Internal medicine</term>
<term>Ischemic</term>
<term>Ischemic npsle</term>
<term>Leiden npsle clinic</term>
<term>Lupus</term>
<term>Lupus anticoagulans</term>
<term>Lupus patients</term>
<term>Multivariate analysis</term>
<term>Neopterin</term>
<term>Npsle</term>
<term>Npsle patients</term>
<term>Parotid</term>
<term>Parotid gland</term>
<term>Parotid glands</term>
<term>Pathogenetic mechanism</term>
<term>Primary syndrome</term>
<term>Renal disease</term>
<term>Retrospective analysis</term>
<term>Rheumatology</term>
<term>Rheumatology clinic</term>
<term>Rheumatology unit</term>
<term>Risk factors</term>
<term>Salivary gland biopsy</term>
<term>Sledai</term>
<term>Syndrome</term>
<term>Systemic disease</term>
<term>Systemic lupus erythematosus</term>
<term>Thrombosis</term>
<term>Univariate analysis</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Background Ten to twenty-five percent of systemic lupus erythemathosus (SLE) patients will progress to end-stage renal disease (ESRD). Data about the survival rate of lupus patients on dialysis is controversial. Objectives The present study reports the survival of SLE patients undergoing dialysis and analyzes factors associated with mortality. Methods Twenty dialysis centers were visited between May/2003 and February/2004. Disease activity was evaluated using the SLE disease activity index (SLEDAI) without the renal related parameters (nrSLEDAI); Clinical examination and laboratory tests were performed at entrance in the study. The control group consisted of hemodialysis patients without SLE, matched for gender, race, age, time on dialysis, and hepatitis C virus (HCV) infection. Patients were followed for 60 months. The end-point was death of any cause. Kaplan-Meier method was used to estimate survival. Associations of risk factors with mortality were tested with the Cox proportional hazards model. Results Each group was composed of 57 patients. The group of SLE tended to have a slightly shorter time on dialysis (54±50 months vs. 71±53 months, P=0.0829). Twelve patients (21%) in each group had HCV infection. The prevalence of flare in SLE patients approached 44%. The 1- and 5-year survival rates of SLE patients and controls were 88 and 70%, 93 and 84%, respectively. When analyzing the Kaplan Meier curves, survival of the control group and the one from SLE patients with nrSLEDAI ≤8 were similar but significantly better than the one of SLE patients with nrSLEDAI>8 (P<0.001). In the univariate analysis, only nrSLEDAI (either as a continuous or a categorical variable, HR 1.176, 95%CI 1.043-1.326, P=0.008, and HR 5.746, 95%CI 1.983-16.651, P=0.001, respectively), immunosuppressive use (HR 2.713, 95%CI 1.032-7.133, P=0.043), and URR (HR 0.967, 95% CI 0.930-1.005, P=0.086) were significantly associated with mortality. In the multivariate analysis, only nrSLEDAI>8 (HR 6.368, 95%CI 1.798-22.548, P=0.004), and URR (HR 0.953, 95%CI 0.917-0.990, P=0.014) emerged as independent factors associated with mortality in lupus patients. Conclusions A high nrSLEDAI was strongly associated with five year mortality in lupus patients on dialysis. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Brésil</li>
</country>
<region>
<li>État de Rio de Janeiro</li>
</region>
<settlement>
<li>Rio de Janeiro</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Fabris, C L" sort="Fabris, C L" uniqKey="Fabris C" first="C. L." last="Fabris">C. L. Fabris</name>
<name sortKey="Lugon, J R" sort="Lugon, J R" uniqKey="Lugon J" first="J. R." last="Lugon">J. R. Lugon</name>
</noCountry>
<country name="Brésil">
<region name="État de Rio de Janeiro">
<name sortKey="Ribeiro, F M" sort="Ribeiro, F M" uniqKey="Ribeiro F" first="F. M." last="Ribeiro">F. M. Ribeiro</name>
</region>
<name sortKey="Bendet, I" sort="Bendet, I" uniqKey="Bendet I" first="I." last="Bendet">I. Bendet</name>
<name sortKey="Bendet, I" sort="Bendet, I" uniqKey="Bendet I" first="I." last="Bendet">I. Bendet</name>
<name sortKey="Ribeiro, F M" sort="Ribeiro, F M" uniqKey="Ribeiro F" first="F. M." last="Ribeiro">F. M. Ribeiro</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001172 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001172 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A7B7080A6053EA00FC190B7DC7F537E8803BAC2F
   |texte=   SAT0221 Survival in lupus patients with end-stage renal disease: A brazilian cohort
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021